文献速递头颈技术与安全CTPET

131I SPECT/CT 对分化型甲状腺癌治疗决策的影响

Impact of 131I SPECT/CT on Therapeutic Decision-Making in Differentiated Thyroid Carcinoma: A Single-Center Retrospective Study.
PubMed 文献 · Acad Radiol · 2026-08-24

本研究回顾性纳入 199 例分化型甲状腺癌患者,比较 WBS 单独与联合 SPECT/CT 对 131I 治疗决策的影响。结果显示 SPECT/CT 在 20.6% 的患者中改变了治疗方案,其中 27 例减少剂量、14 例增加剂量。SPECT/CT 最大价值在于淋巴结评估,有利于个体化治疗。

要点

  • SPECT/CT 可显著改善 131I 摄取灶的解剖定位,尤其在颈部及淋巴结区。
  • 约五分之一患者因 SPECT/CT 改变治疗剂量,应重视其在剂量决策前的作用。
  • 淋巴结评估一致性中等,阅片时需重点观察颈部和纵隔淋巴结。

核心结论

  • SPECT/CT 在分化型甲状腺癌中具有显著临床价值,约五分之一患者因此减少过度治疗或治疗不足。
  • SPECT/CT 对淋巴结的定性优势最突出,但对 T 分期、M 分期和风险分层的总体一致性已很高。

研究设计与样本

  • 单中心回顾性研究,纳入 199 例 2011 至 2017 年在一家三级学术中心治疗的分化型甲状腺癌患者。
  • 比较基于 WBS 的治疗决策与联合 SPECT/CT 后的治疗决策,一致性采用 ICC 和 Kappa 评估。

关键影像表现/征象

  • WBS 上颈部摄取、淋巴结受累表现是治疗方案改变的重要影像预测因素。
  • SPECT/CT 通过精确定位 131I 摄取灶,区分淋巴结、甲状腺残留、骨骼或其他部位。
  • 骨转移灶在手术切除后可导致剂量下调而非上调,SPECT/CT 帮助准确分期与疗效评估。

诊断标准与关键数值

  • SPECT/CT 改变了 20.6%(41/199)患者的治疗管理。
  • 41 例改变者中,27 例(65.9%)减少 131I 活度,14 例(34.1%)增加 131I 活度。
  • 41 例改变者中,26 例(63.4%)降期,15 例(36.6%)升期。
  • 总体剂量一致性良好:ICC = 0.833,95% CI 0.785~0.871。
  • T 分期 κ = 0.977,M 分期 κ = 0.931,风险分层 κ = 0.971,淋巴结评估 κ = 0.589,95% CI 0.478~0.700。

临床应用与阅片要点

  • 131I 治疗剂量决策前加做 SPECT/CT,有助于避免对良性摄取灶的过度治疗。
  • 对于 WBS 显示颈部或淋巴结摄取者,应积极使用 SPECT/CT 明确性质与范围。
  • 报告时应重点描述 SPECT/CT 所示的淋巴结数目、位置、大小及与 131I 摄取的关系。
  • 既往累积剂量较高或计划剂量处于临界值时,SPECT/CT 有助于剂量调整。

局限性

  • 本研究为单中心回顾性设计。
  • 淋巴结评估一致性中等(κ = 0.589),提示该区域判读仍存在一定难度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: Differentiated thyroid carcinoma (DTC) has a favorable prognosis when properly managed. Whole-body scanning (WBS) is the standard functional imaging method for post-surgical staging; however, its limited spatial resolution may lead to misclassification of iodine-131 (131I) uptake sites. Single-photon emission computed tomography/computed tomography (SPECT/CT) improves anatomical localization and diagnostic accuracy. We aimed to evaluate the incremental clinical value of SPECT/CT over WBS in determining the 131I therapeutic dose in patients with DTC.

MATERIALS AND METHODS: This retrospective study included 199 patients with DTC treated at a tertiary academic center between 2011 and 2017. WBS-based management decisions were compared with those incorporating SPECT/CT findings. Agreement was assessed using the intraclass correlation coefficient (ICC) and Kappa.

RESULTS: SPECT/CT changed therapeutic management in 20.6% of patients (n = 41). The administered 131I activity was reduced in 27 of these patients (65.9%), preventing overtreatment, and increased in 14 (34.1%), preventing undertreatment. By staging, 26 patients (63.4%) were downstaged, and 15 (36.6%) were upstaged; in one upstaged patient, a surgically resected bone metastasis led to a dose reduction rather than an increase. Overall dose agreement was good (ICC = 0.833; 95% confidence interval [CI]: 0.785-0.871). Concordance was very high for T staging (κ = 0.977), M staging (κ = 0.931), and risk category (κ = 0.971), but only moderate for lymph node evaluation (κ = 0.589; 95% CI: 0.478-0.700). Predictors of management change included: cervical uptake (P < 0.001), lymph node involvement on WBS (P = 0.004), proposed WBS dose (P = 0.013), cumulative prior 131I dose (P = 0.027), and undetectable antithyroglobulin antibodies (P = 0.032).

CONCLUSION: SPECT/CT after WBS has a significant clinical impact in DTC, enabling more personalized therapy and reducing both undertreatment and overtreatment in approximately one-fifth of patients, with its greatest contribution in lymph node characterization.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Pontes, Verçosa, Lima, et al. Impact of 131I SPECT/CT on Therapeutic Decision-Making in Differentiated Thyroid Carcinoma: A Single-Center Retrospective Study. Acad Radiol. 2026. PMID: 42637579. doi:10.1016/j.acra.2026.08.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。